针对第2大类CRISPR-Cas系统的acr基因的发现及Acr蛋白多样化的抑制机制

CRISPR-Cas系统是细菌和古细菌来源的RNA介导的适应性免疫系统,利用RNA介导的核酸酶活性抵抗以噬菌体为代表的外源核酸的入侵.为逃避这种来源于宿主的免疫反应,噬菌体进化出了较小的anti-CRISPR蛋白(Acr). Acrs采用不同的抑制策略,将Cas效应蛋白限制在不同的阶段,从而使其失活.随着Cas蛋白在生物技术领域和临床上的广泛应用, Acr已被开发为有用的调控工具.对Acr的研究不仅可以加深人们对Cas蛋白别构调控的理解,而且可以为开发新型的基于Acr的调控工具打下基础.利用实验和生物信息学的手段,越来越多的Acr被发现,其中第2大类CRISPR-Cas系统目前有大约50种.本综述聚焦于第2大类CRISPR-Cas系统的Acr,从基因发现、抑制机制和技术应用三个方面对其进行总结,并对未来的研究方向做出展望.     

CRISPR/Cas12a系统：核酸检测的多功能工具

规律成簇的间隔短回文重复序列（clustered regularly interspaced short palindromic repeats,CRISPR）是原核生物的适应性免疫系统,对抗外来遗传物质（如质粒和噬菌体）的攻击。近年来,科学家们发现了一种新型基因编辑工具,一种强大的分子剪刀CRISPR/Cas12a系统,该系统在对靶标DNA进行切割的同时还具有对体系内单链DNA进行任意切割的活性,并将其转移到体外检测系统。本文对CRISPR/Cas12a系统组成、结构、Cas12a与Cas9的对比和CRISPR/Cas12a系统在核酸检测中的应用进行了综述。     

CRISPR/Cas9高通量筛选技术与肿瘤治疗

成簇规律间隔短回文重复(clustered regularly interspaced short palindromic repeats, CRISPR),是细菌或古菌在与噬菌体长期生存进化获得的一种免疫系统. 根据Cas蛋白(CRISPR-associated protein)的不同,CRISPR系统可分为3种. 其中II型CRISPR/Cas9已被改造成为一种有效的基因编辑工具,并运用于多种物种基因的改造. 作为1种基因编辑的手段,CRISPR/Cas9技术通过诱导DNA双链断裂损伤,进一步干扰基因的表达. 与传统的基因编辑技术相比,CRISPR/Cas9技术显示出效率高、成本低和易操作等特点. 与此同时,二代测序技术的发展促进全基因组的解析. CRISPR技术结合高通量二代测序手段的使用,在肿瘤的治疗领域中已发挥出了独特的优势. 本文就近年来CRISPR/Cas9高通量筛选技术的发展,及其在肿瘤治疗过程中的应用进行综述.     

CRISPR/Cas9技术特异杀伤癌细胞——癌症治疗新策略北大核心CSCD

CRISPR/Cas9技术,主要用于基因编辑。最近发现,CRISPR/Cas9技术亦可用于特异性杀伤癌细胞。天然状态下,CRISPR/Cas9系统存在于细菌,其功能是识别并切割入侵病毒或噬菌体的DNA,由此导致病毒或噬菌体死亡。因此,对于细菌来说,CRISPR/Cas9是一种＂基因剪刀＂或＂基因武器＂,是细菌重要的＂免疫系统＂。目前,CRISPR/Cas9系统一般用于对单基因或多基因的敲除或插入,以构建细胞或动物研究模型。     

CRISPR-Cas系统介导的基因组编辑和基因转录调控

CRISPR是一个特殊的DNA重复序列家族,其基因结构的主体是由同向重复序列(repeat)与间隔序列(spacer)构成的多段R-S结构组成,称为CRISPR基因座(CRISPR locus)。在CRISPR位点的一端存在几组编码蛋白质的基因序列,称为CRISPR相关(CRISPR-associated,Cas)基因,其编码的蛋白质称为CAS蛋白。利用CRISPR-Cas9系统对DNA分子的靶向切割特性,使其可被用于定向的基因修饰。除用于定点的基因编辑,CRISPR-Cas系统也可用于干扰目的基因的转录。     

CRISPR/Cas9技术特异杀伤癌细胞——癌症治疗新策略

<正>CRISPR/Cas9技术,主要用于基因编辑。最近发现,CRISPR/Cas9技术亦可用于特异性杀伤癌细胞。天然状态下,CRISPR/Cas9系统存在于细菌,其功能是识别并切割入侵病毒或噬菌体的DNA,由此导致病毒或噬菌体死亡。因此,对于细菌来说,CRISPR/Cas9是一种"基因剪刀"或"基因武器",是细菌重要的"免疫系统"。目前,CRISPR/Cas9系统一般用于对单基因或多基因的敲除或插入,以构建细胞或动物研究模型。     

腾冲嗜热厌氧杆菌Cas2原核表达及生物信息学分析

为研究CRISPR/Cas系统及其相关蛋白Cas2(TTE2657)在腾冲嗜热厌氧杆菌热适应中的作用,应用PCR技术构建了原核重组质粒pET-28a::cas2,并在大肠埃希菌BL21表达Cas2蛋白;结合生物信息学软件对cas2编码蛋白的基本理化性质、氨基酸同源性、空间结构及蛋白质相互作用网络进行预测和分析。结果显示,成功构建了原核表达载体pET-28a::cas2并在大肠埃希菌BL21中得到表达,Cas2分子质量大小为9.9 ku,主要以可溶性形式存在;qRT-PCR显示cas2 mRNA在60℃和75℃高表达;生物信息学分析显示cas2基因其完整的ORF全长264 bp,编码88个氨基酸,其中Ile(14)、Ser(14)、Phe (12)含量较高,等电点为9.31,不存在跨膜结构。其蛋白质二级空间结构以α-螺旋、无规则卷曲、β-折叠为主,蛋白互作预测网络显示Cas2与Cas3、Cas5、Cas7等其家族大部分蛋白存在相互作用。进化树分析显示腾冲嗜热厌氧杆菌cas2基因与厌氧菌芽胞杆菌B7M1同源性最高(39.5%)。腾冲嗜热厌氧杆菌cas2编码蛋白是一种亲水性蛋白,在原核系统能高效表达。本研究为嗜热蛋白质的热稳定性机制的研究提供参考。     

从大容量噬菌体抗体库中筛选抗Acr蛋白人源单链抗体

目的:从天然的大容量噬菌体抗体库中筛选特异的抗结核分枝杆菌晶体蛋白( alpha-crystallin Acr)的人源抗体.方法:以结核分枝杆菌Acr蛋白包被免疫管,通过对噬菌体抗体库进行4轮“吸附-洗脱-扩增”的过程从大容量抗体库中筛选特异性抗结核分枝杆菌Acr蛋白的抗体,并对可变区序列进行了测序分析.将特异性的噬菌体抗体感染HB2151菌,经IPTG诱导表达,制备了抗结核分枝杆菌Acr蛋白的可溶性单链抗体;对其序列和抗原结合活性进行分析鉴定.结果:经过4轮筛选,获得了43个与结核分枝杆菌Acr蛋白结合的阳性克隆,其中29个特异结合的克隆;测序分析有26不同的可变区片段;通过可溶性单链抗体(scFv)表达筛选到14株特异性结合Acr蛋白的可溶性单链抗体克隆;经过基因测序,分析了可变区基因的亚群.成功制备了可溶性单链抗体.Westren blotting分析证实筛选的人源单链抗体能与天然蛋白结合.结论:利用单链大容量抗体库获得抗结核分枝杆菌Acr蛋白的噬菌体抗体并且成功制备抗结核分枝杆菌Acr天然蛋白的可溶性单链抗体,为今后的研究和应用奠定基础.     

CRISPR/Cas系统：RNA靶向的基因组定向编辑新技术

CRISPR/Cas系统广泛存在于细菌及古生菌中, 是机体长期进化形成的RNA指导的降解入侵病毒或噬菌体DNA的适应性免疫系统。对Ⅱ型CRISPR/Cas系统的改造使其成为继锌指核酸酶(ZFNs)和TALE核酸酶(TALENs)以来的另一种对基因组进行高效定点修饰的新技术, 与ZFNs和TALENs相比, CRISPR/Cas系统更简单, 并且更容易操作。文章重点介绍了Ⅱ型CRISPR/Cas系统的基本结构、作用原理及这一技术在基因组定点修饰中的应用, 剖析了该技术可能存在的问题, 展望了CRISPR/Cas系统的应用前景, 为开展这一领域的研究工作提供参考。     

基于CRISPR-Cas系统的基因组定点修饰新技术

CRISPR(clustered regulatory interspersed short palindromic repeat)序列源于原核生物的一种获得性免疫系统,协同Cas(CRISPR-associated)蛋白家族参与抵抗噬菌体或其它病毒的二次感染,广泛存在于细菌(60%)和古菌(90%)中.病菌和宿主的共同进化导致了CRISPR-Cas系统具有多样性,可分为3大类(Ⅰ-Ⅲ),又分为10亚类.在Ⅱ型CRISPR-Cas系统基础上建立了RNA介导的CRISPR-Cas系统来修饰(删除、添加、激活、抑制)靶细胞中特定的基因序列,现已在人类细胞、小鼠、斑马鱼、酵母、细菌、果蝇、线虫、拟南芥中得以应用.本文主要介绍了Ⅱ型CRISPR-Cas系统的结构特点、作用机理及作为新型基因组定点修饰技术的研究进展,分析该技术优势,并展望CRISPRCas系统的应用前景.     

The novel anti-CRISPR AcrIIA22 relieves DNA torsion in target plasmids and impairs SpyCas9 activity

To overcome CRISPR-Cas defense systems, many phages and mobile genetic elements (MGEs) encode CRISPR-Cas inhibitors called anti-CRISPRs (Acrs). Nearly all characterized Acrs directly bind Cas proteins to inactivate CRISPR immunity. Here, using functional metagenomic selection, we describe AcrIIA22, an unconventional Acr found in hypervariable genomic regions of clostridial bacteria and their prophages from human gut microbiomes. AcrIIA22 does not bind strongly to SpyCas9 but nonetheless potently inhibits its activity against plasmids. To gain insight into its mechanism, we obtained an X-ray crystal structure of AcrIIA22, which revealed homology to PC4-like nucleic acid–binding proteins. Based on mutational analyses and functional assays, we deduced that acrIIA22 encodes a DNA nickase that relieves torsional stress in supercoiled plasmids. This may render them less susceptible to SpyCas9, which uses free energy from negative supercoils to form stable R-loops. Modifying DNA topology may provide an additional route to CRISPR-Cas resistance in phages and MGEs.

Derived from phages of the gut microbiome, this study describes a CRISPR-Cas9 inhibitor with an unexpected mechanism; instead of binding Cas9 itself, this “anti-CRISPR” relaxes plasmid DNA and enables Cas9 evasion, suggesting that DNA topology is an underappreciated battleground in phage-bacterial conflicts.     

Three CRISPR-Cas immune effector complexes coexist in Pyrococcus furiosus

CRISPR-Cas immune systems function to defend prokaryotes against potentially harmful mobile genetic elements including viruses and plasmids. The multiple CRISPR-Cas systems (Types I, II, and III) each target destruction of foreign nucleic acids via structurally and functionally diverse effector complexes (crRNPs). CRISPR-Cas effector complexes are comprised of CRISPR RNAs (crRNAs) that contain sequences homologous to the invading nucleic acids and Cas proteins specific to each immune system type. We have previously characterized a crRNP in Pyrococcus furiosus (Pfu) that contains Cmr (Type III-B) Cas proteins associated with one of two size classes of crRNAs and cleaves complementary target RNAs. Here, we have isolated and characterized two additional native Pfu crRNPs containing either Csa (Type I-A) or Cst (Type I-G) Cas proteins and distinct profiles of associated crRNAs. For each complex, the Cas proteins were identified by mass spectrometry and immunoblotting and the crRNAs by RNA sequencing and Northern blot analysis. The crRNAs associated with both the Csa and Cst complexes originate from all seven Pfu CRISPR loci and contain identical 5′ ends (8-nt repeat-derived 5′ tag sequences) but heterogeneous 3′ ends (containing variable amounts of downstream repeat sequences). These crRNA forms are distinct from Cmr-associated crRNAs, indicating different 3′ end processing pathways following primary cleavage of common pre-crRNAs. Like other previously characterized Type I CRISPR-Cas effector complexes, we predict that the newly identified Pfu Csa and Cst crRNPs each function to target invading DNA, adding an additional layer of protection beyond that afforded by the previously characterized RNA targeting Cmr complex.     

Cas5d Protein Processes Pre-crRNA and Assembles into a Cascade-like Interference Complex in Subtype I-C/Dvulg CRISPR-Cas System

Clustered regularly interspaced short palindromic repeats (CRISPRs), together with an operon of CRISPR-associated (Cas) proteins, form an RNA-based prokaryotic immune system against exogenous genetic elements. Cas5 family proteins are found in several type I CRISPR-Cas systems. Here, we report the molecular function of subtype I-C/Dvulg Cas5d from Bacillus halodurans. We show that Cas5d cleaves pre-crRNA into unit length by recognizing both the hairpin structure and the 3' single stranded sequence in the CRISPR repeat region. Cas5d structure reveals a ferredoxin domain-based architecture and a catalytic triad formed by Y46, K116, and H117 residues. We further show that after pre-crRNA processing, Cas5d assembles with crRNA, Csd1, and Csd2 proteins to form a multi-sub-unit interference complex similar to Escherichia coli Cascade (CRISPR-associated complex for antiviral defense) in architecture. Our results suggest that formation of a crRNA-presenting Cascade-like complex is likely a common theme among type I CRISPR subtypes.     

Decoupling the bridge helix of Cas12a results in a reduced trimming activity,increased mismatch sensitivity and impaired conformational transitions

The widespread and versatile prokaryotic CRISPR–Cas systems (clustered regularly interspaced short palindromic repeats and associated Cas proteins) constitute powerful weapons against foreign nucleic acids. Recently, the single-effector nuclease Cas12a that belongs to the type V CRISPR–Cas system was added to the Cas enzymes repertoire employed for gene editing purposes. Cas12a is a bilobal enzyme composed of the REC and Nuc lobe connected by the wedge, REC1 domain and bridge helix (BH). We generated BH variants and integrated biochemical and single-molecule FRET (smFRET) studies to elucidate the role of the BH for the enzymatic activity and conformational flexibility of Francisella novicida Cas12a. We demonstrate that the BH impacts the trimming activity and mismatch sensitivity of Cas12a resulting in Cas12a variants with improved cleavage accuracy. smFRET measurements reveal the hitherto unknown open and closed state of apo Cas12a. BH variants preferentially adopt the open state. Transition to the closed state of the Cas12a-crRNA complex is inefficient in BH variants but the semi-closed state of the ternary complex can be adopted even if the BH is deleted in its entirety. Taken together, these insights reveal that the BH is a structural element that influences the catalytic activity and impacts conformational transitions of FnCas12a.     

CRISPR_Cas systems for fungal research

Genome-editing CRISPR-Cas systems, using Cas9 and Cas12a endonucleases, have improved our ability to precisely edit genomes and control gene expression. We summarize here the knowledge gained from using CRISPR-Cas9 and CRISPR-Cas12a in fungal research. Also discussed are strategies developed for limiting the occurrences of off-target mutations caused by CRISPR-Cas genome editing.     

Phage Against the Machine: Discovery and Mechanism of Type V Anti-CRISPRs

The discovery of diverse bacterial CRISPR-Cas systems has reignited interest in understanding bacterial defense pathways while yielding exciting new tools for genome editing. CRISPR-Cas systems are widely distributed in prokaryotes, found in 40% of bacteria and 90% of archaea, where they function as adaptive immune systems against bacterial viruses (phage) and other mobile genetic elements. In turn, phage have evolved inhibitors, called anti-CRISPR proteins, to prevent targeting. Type V CRISPR-Cas12 systems have emerged as a particularly exciting arena in this co-evolutionary arms race. Type V anti-CRISPRs have highly diverse and novel mechanisms of action, some of which appear to be unusually potent or widespread. In this review, we discuss the discovery and mechanism of these anti-CRISPRs as well as future areas for exploration.